Review on Stem Cell Therapy: An Approach to Combat Cancer Proliferation
Abstract
Cancer is currently one of the leading causes of death worldwide. Treatment as well as minimising morbidity and mortality is a significant challenge. Stem cell therapy is one of the finest approaches to combat tumor metastasis. Moreover, in planning the approach to cancer treatment through stem cell therapy, there are several challenges, such as the concern of durability and tumorigenesis. There are many other benefits of using stem cell therapy, such as its application in regenerative medicine. Additionally, Utilising stem cell therapy is not an easy task as it requires different parameters and factors to be appropriately monitored, such as route of transplantation, cell number etc. The selection
of specific stem cell types is one of the prominent steps in stem cell therapy. Stem cell moves to the metastatic location and helps in site-specific anti-tumour agent delivery. At the same time, there are several challenges, such as treatment success, side effects of stem cell transplant, tumorigenesis concerns, etc. Despite some challenges, we cannot deny that stem cell therapy is a promising approach to combat metastasis in different types of neoplasm. Hence, a systematic and deep study is required to overcome the potential challenges. This review article deals with studying various aspects of stem cell therapy that is a source of stem cells, different modes of transplant, implications for cancer treatment, factors influencing stem cell therapies, challenges to stem cell therapy etc. So, the present review work attempts to highlight various important aspects of targeting cancer with a stem cell approach
Full Text:
PDFReferences
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111. doi:10.1038/35102167
Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma. 2005;52(6):435-440.
Kim CFB, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6):823-835. doi:10.1016/j.cell.2005.03.032
Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41-49. doi:10.1038/nature00870
Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature. 2005;435(7044):974-978. doi:10.1038/nature03816
Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144-2151. doi:10.1016/j.biocel.2012.08.022
Sharkis SJ, Jones RJ, Civin C, Jang Y-Y. Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med. 2012;4(127):127ps9. doi:10.1126/scitranslmed.3003920
Xiao J, Mu J, Liu T, Xu H. Dig the root of cancer: targeting cancer stem cells therapy. J Med Discov. 2017;2(2):1-6.
Zhang C-L, Huang T, Wu B-L, He W-X, Liu D. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8(43):75756-75766. doi:10.18632/oncotarget.20798
Stem cell transplants in cancer treatment. Natl Cancer Inst. Published online 2015.
Types of stem cell and bone marrow transplants. American Cancer Society.
Finlan LE, Hupp TR. Epidermal stem cells and cancer stem cells: insights into cancer and potential therapeutic strategies. Eur J Cancer. 2006;42(9):1283-1292. doi:10.1016/j.ejca.2006.01.047
Bixby S, Kruger GM, Mosher JT, Joseph NM, Morrison SJ. Cell-intrinsic differences between stem cells from different regions of the peripheral nervous system regulate the generation of neural diversity. Neuron. 2002;35(4):643-656. doi:10.1016/s0896-6273(02)00825-5
SOUTHAM CM. Relationships of immunology to cancer: a review. Cancer Res. 1960;20:271-291.
Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res. 2003;34(6):507-514. doi:10.1016/j.arcmed.2003.08.007
Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst. 1971;46(2):411-422.
Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A. 2003;100(7):3547-3549. doi:10.1073/pnas.0830967100
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737. doi:10.1038/nm0797-730
Galderisi U, Cipollaro M, Giordano A. Stem cells and brain cancer. Cell Death Differ. 2006;13(1):5-11. doi:10.1038/sj.cdd.4401757
Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14(1):43-47. doi:10.1016/j.gde.2003.11.007
Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100(25):15178-15183. doi:10.1073/pnas.2036535100
Wang JCY, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15(9):494-501. doi:10.1016/j.tcb.2005.07.004
Knudson AGJ, Strong LC, Anderson DE. Heredity and cancer in man. Prog Med Genet. 1973;9:113-158.
Morrison SJ, Qian D, Jerabek L, et al. A genetic determinant that specifically regulates the frequency of hematopoietic stem cells. J Immunol. 2002;168(2):635-642. doi:10.4049/jimmunol.168.2.635
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988. doi:10.1073/pnas.0530291100
Cozzio A, Passegué E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17(24):3029-3035. doi:10.1101/gad.1143403
Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667. doi:10.1056/NEJMoa040258
Weissman IL. Normal and neoplastic stem cells. Novartis Found Symp. 2005;265:34-35,92-97.
Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58):9392-9400. doi:10.1038/sj.onc.1208311
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401. doi:10.1038/nature03128
Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021. doi:10.1158/0008-5472.CAN-04-1364
Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A. 2005;102(19):6942-6947. doi:10.1073/pnas.0502320102
Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147. doi:10.1126/science.282.5391.1145
Serakinci N, Guldberg P, Burns JS, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene. 2004;23(29):5095-5098. doi:10.1038/sj.onc.1207651
Sylvester KG, Longaker MT. Stem cells: review and update. Arch Surg. 2004;139(1):93-99. doi:10.1001/archsurg.139.1.93
Simonsen JL, Rosada C, Serakinci N, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 2002;20(6):592-596. doi:10.1038/nbt0602-592
Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832-843. doi:10.1056/NEJM197504172921605
Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013;5(184):184ra59. doi:10.1126/scitranslmed.3005365
Ebrahimi S, Ghorbani E, Khazaei M, et al. Interferon‐mediated tumor resistance to oncolytic virotherapy. J Cell Biochem. 2017;118(8):1994-1999.
Atherton MJ, Lichty BD. Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy. 2013;5(11):1191-1206. doi:10.2217/imt.13.123
Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846-12851. doi:10.1073/pnas.97.23.12846
Miska J, Lesniak MS. Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme. EBioMedicine. 2015;2(8):774-775. doi:10.1016/j.ebiom.2015.08.022
Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26(3):151-168. doi:10.1053/ctrv.1999.0161
Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253-1261. doi:10.1056/NEJMra061808
Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60(16):4403-4411.
Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci. 2002;99(25):16220-16225.
Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 2001;294(5549):2186-2189. doi:10.1126/science.1065518
Park I, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423(6937):302-305. doi:10.1038/nature01587
Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89(9):3104-3112.
Okabe M, Otsu M, Ahn DH, et al. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood. 2009;114(9):1764-1767. doi:10.1182/blood-2009-02-203695
Barriga F, Wietstruck A, Rojas N, et al. [Allogenic hematopoietic stem cell transplantation with unrelated cord blood: report of three cases from the Chilean cord blood bank]. Rev Med Chil. 2013;141(8):1064-1067. doi:10.4067/S0034-98872013000800014
Renga M, Pedrazzoli P, Siena S. Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2003;14(8):1177-1184. doi:10.1093/annonc/mdg317
Vatakis DN, Koya RC, Nixon CC, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2011;108(51):E1408-16. doi:10.1073/pnas.1115050108
Gschweng E, De Oliveira S, Kohn DB. Hematopoietic stem cells for cancer immunotherapy. Immunol Rev. 2014;257(1):237-249. doi:10.1111/imr.12128
Golubeva V, Mikhalevich J, Novikova J, Tupizina O, Trofimova S, Zueva Y. Novel cell population data from a haematology analyzer can predict timing and efficiency of stem cell transplantation. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2014;50(1):39-45. doi:10.1016/j.transci.2013.12.004
Hansen K, Müller F-J, Messing M, et al. A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells. Neuro Oncol. 2010;12(7):645-654. doi:10.1093/neuonc/noq002
Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11(1):25. doi:10.1186/s13148-018-0587-8
Lou W, Liu J, Gao Y, et al. MicroRNA regulation of liver cancer stem cells. Am J Cancer Res. 2018;8(7):1126-1141.
Bagó JR, Sheets KT, Hingtgen SD. Neural stem cell therapy for cancer. Methods. 2016;99:37-43. doi:10.1016/j.ymeth.2015.08.013
Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys. 2009;75(3):843-853. doi:10.1016/j.ijrobp.2008.06.1953
Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029. doi:10.1371/journal.pmed.1000029
Røsland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow–derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69(13):5331-5339.
Refbacks
- There are currently no refbacks.